Healthcare / BiotechnologyShenzhen
$6.90
+0.20 (+2.99%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-139.8M · quality 44.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
27/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.8B
P/E
690.0x
↑EV/EBITDA
46.2x
↑ROE
1.5%
↑Gross Margin
64.0%
↑Debt/Equity
0.50
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-27.4%
FCF CAGR
—
FCF margin
8.0%
FCF / Net income
1.53x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $263.2M · net income $13.7M · FCF $21.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $263.2M | $263.2M | $224.2M | $254.1M | $686.9M |
| Net Income | $13.7M | $13.7M | $17.1M | $-184.9M | $83.0M |
| EBITDA | $69.7M | $69.7M | $59.7M | $-133.7M | $129.3M |
| EPS | 0.03 | 0.03 | 0.04 | -0.46 | 0.21 |
| Gross Margin | 64.0% | 64.0% | 70.6% | 49.9% | 56.5% |
| Operating Margin | 10.0% | 10.0% | 18.2% | -26.3% | 20.0% |
| Net Margin | 5.2% | 5.2% | 7.6% | -72.8% | 12.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.50 | 0.50 | 0.54 | 0.43 | 0.12 |
| Current Ratio | 7.29 | 7.29 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $21.0M | $21.0M | $-139.8M | $-165.9M | $-24.3M |
| Returns | |||||
| ROE | 1.5% | 1.5% | 2.0% | -21.8% | 8.6% |
| Valuation | |||||
| P/E | 690.00 | 690.00 | 199.75 | — | 81.05 |
| EV/EBITDA | 46.16 | 46.16 | 60.24 | — | 51.00 |
| P/B | 3.50 | 3.50 | 3.93 | 5.43 | 6.97 |
| Growth & Yield | |||||
| Revenue Growth | 17.4% | 17.4% | -11.7% | -63.0% | — |
| EPS Growth | -25.0% | -25.0% | 108.7% | -319.0% | — |
| Dividend Yield | 0.4% | 0.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
173.3%
EPS terminal req.
$0.61
Spread vs growth
-198.3%
5Y implied EPS CAGR
89.9%
EPS terminal req.
$0.74
Spread vs growth
-114.9%
10Y implied EPS CAGR
44.5%
EPS terminal req.
$1.19
Spread vs growth
-69.5%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-24.8%
Start / end P/E
230.5x → 230.0x
EPS bridge
0.04 → 0.03
Residual
+0.1%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.